首頁 › 非霍奇金淋巴瘤 › 田納西州 › Nashville
Nashville, TN 的 非霍奇金淋巴瘤 臨床試驗
21 項針對 非霍奇金淋巴瘤 的研究正在 Nashville（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
招募中1/2 期
- Tennessee Oncology, Pllc Nashville, Nashville
Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
招募中2 期
- Vanderbilt University/Ingram Cancer Center, Nashville
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
招募中1/2 期
- SCRI Oncology Partners ( Site 0100), Nashville
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
招募中2 期
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute, Nashville
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
招募中1 期
- SCRI Oncology Partners, Nashville
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
招募中1 期
- Sarah Cannon Research Institute, Nashville
- Vanderbilt University Medical Center, Nashville
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
招募中1 期
- Scri Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
招募中2 期
- Research Site, Nashville
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
招募中2 期
- Tennessee Oncology, Nashville
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
招募中1 期
- SCRI Oncology Partners, Nashville
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
招募中1/2 期
- Research Site, Franklin · 距離 17 英里
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
招募中1/2 期
- Vanderbilt University Medical Center, Nashville
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
招募中3 期
- Sarah Cannon Research Institute SCRI, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
招募中1/2 期
- TriStar BMT, Nashville
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
招募中3 期
- SCRI Oncology Partners, Nashville
DALY II USA/ MB-CART2019.1 for DLBCL
招募中2 期
- SCRI Oncology Partners, Nashville
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
招募中觀察性研究
- Vanderbilt University, Nashville
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
招募中4 期
- Tennessee Oncology, Nashville
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
招募中4 期
- Tennessee Oncology, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Nashville
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
招募中1/2 期
- SCRI Oncology Partners, Nashville
其他城市的 非霍奇金淋巴瘤 試驗
- Houston, TX31 項研究
- New York City, NY31 項研究
- Boston, MA26 項研究
- Philadelphia, PA20 項研究
- Baldwin Park, CA19 項研究
- Washington, DC18 項研究
- Chicago, IL18 項研究
- Milwaukee, WI18 項研究
- Atlanta, GA18 項研究
- Columbus, OH18 項研究
- Dallas, TX17 項研究
- Seattle, WA16 項研究
Nashville 的其他研究
- 非小細胞肺癌97 項研究
- 乳癌81 項研究
- 轉移性癌症70 項研究
- 大腸直腸癌69 項研究
- 癌症（所有類型）65 項研究
- 卵巢癌49 項研究
- 前列腺癌43 項研究
- 肺癌40 項研究
- 頭頸部鱗狀細胞癌39 項研究
- 胰臟癌39 項研究
- 子宮內膜癌38 項研究
- 黑色素瘤33 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。